These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400 [TBL] [Abstract][Full Text] [Related]
7. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507 [TBL] [Abstract][Full Text] [Related]
8. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194 [TBL] [Abstract][Full Text] [Related]
9. Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study. Ukkonen M; Vahvelainen T; Hämäläinen P; Dastidar P; Elovaara I Mult Scler; 2009 Sep; 15(9):1055-61. PubMed ID: 19556313 [TBL] [Abstract][Full Text] [Related]
11. MRI time series modeling of MS lesion development. Meier DS; Guttmann CR Neuroimage; 2006 Aug; 32(2):531-7. PubMed ID: 16806979 [TBL] [Abstract][Full Text] [Related]
12. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253 [TBL] [Abstract][Full Text] [Related]
13. Posterior fossa lesion volume and slowed information processing in multiple sclerosis. Archibald CJ; Wei X; Scott JN; Wallace CJ; Zhang Y; Metz LM; Mitchell JR Brain; 2004 Jul; 127(Pt 7):1526-34. PubMed ID: 15090476 [TBL] [Abstract][Full Text] [Related]
14. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Sormani MP; Rovaris M; Comi G; Filippi M Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123 [TBL] [Abstract][Full Text] [Related]
15. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Rovaris M; Gallo A; Valsasina P; Benedetti B; Caputo D; Ghezzi A; Montanari E; Sormani MP; Bertolotto A; Mancardi G; Bergamaschi R; Martinelli V; Comi G; Filippi M Neuroimage; 2005 Feb; 24(4):1139-46. PubMed ID: 15670691 [TBL] [Abstract][Full Text] [Related]
16. A randomized crossover study of bee sting therapy for multiple sclerosis. Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950 [TBL] [Abstract][Full Text] [Related]
17. Correlations between structural CNS damage and functional MRI changes in primary progressive MS. Filippi M; Rocca MA; Falini A; Caputo D; Ghezzi A; Colombo B; Scotti G; Comi G Neuroimage; 2002 Mar; 15(3):537-46. PubMed ID: 11848696 [TBL] [Abstract][Full Text] [Related]
18. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis]. Lebrun C Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396 [TBL] [Abstract][Full Text] [Related]
19. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status. Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142 [TBL] [Abstract][Full Text] [Related]
20. Tactile-associated recruitment of the cervical cord is altered in patients with multiple sclerosis. Agosta F; Valsasina P; Caputo D; Stroman PW; Filippi M Neuroimage; 2008 Feb; 39(4):1542-8. PubMed ID: 18061484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]